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Introduction: Meticillin-resistant  Staphylococcus 
aureus  (MRSA) is a major cause of healthcare-asso-
ciated infections. Aim: We describe MRSA coloni-
sation/infection and bacteraemia rate trends in 
Dutch–German border region hospitals (NL–DE-BRH) 
in 2012–16. Methods: All 42 NL–DE BRH (8 NL-BRH, 
34 DE-BRH) within the cross-border network EurSafety 
Health-net provided surveillance data (on average ca 
620,000 annual hospital admissions, of these 68.0% 
in Germany). Guidelines defining risk for MRSA colo-
nisation/infection were reviewed. MRSA-related 
parameters and healthcare utilisation indicators were 
derived. Medians over the study period were com-
pared between NL- and DE-BRH. Results: Measures 
for MRSA cases were similar in both countries, how-
ever defining patients at risk for MRSA differed. The 
rate of nasopharyngeal MRSA screening swabs was 
14 times higher in DE-BRH than in NL-BRH (42.3 vs 
3.0/100 inpatients; p < 0.0001). The MRSA incidence 
was over seven times higher in DE-BRH than in NL-BRH 
(1.04 vs 0.14/100 inpatients; p < 0.0001). The nosoco-
mial MRSA incidence-density was higher in DE-BRH 
than in NL-BRH (0.09 vs 0.03/1,000 patient days; 
p = 0.0002) and decreased significantly in DE-BRH 
(p = 0.0184) during the study. The rate of MRSA iso-
lates from blood per 100,000 patient days was almost 
six times higher in DE-BRH than in NL-BRH (1.55 vs 
0.26; p = 0.0041). The patients had longer hospital 
stays in DE-BRH than in NL-BRH (6.8 vs 4.9; p < 0.0001). 
DE-BRH catchment area inhabitants appeared to be 
more frequently hospitalised than their Dutch counter-
parts. Conclusions: Ongoing IPC efforts allowed MRSA 
reduction in DE-BRH. Besides IPC, other local factors, 
including healthcare systems, could influence MRSA 
epidemiology.
Introduction
Cross-border patient mobility is a priority in the 
European Union (EU), because the most accessible or 
appropriate care for citizens living in border regions 
may be available abroad. When, in 2013, the direc-
tive 2011/24/EU came into force, patients’ right to 
access healthcare in other Member States including 
reimbursement and medical follow-up in their respec-
tive home countries was entitled in an EU law for the 
first time. With this, cross-border cooperation in infec-
tion prevention and control (IPC) using comprehensive 
strategies is important [1].
Antimicrobial resistant (AMR) pathogens are a serious 
threat to public health in Europe, leading to increased 
healthcare costs, treatment failure and deaths. For inva-
sive bacterial infections, prompt treatment with effec-
tive antimicrobial agents is essential and is one of the 
most effective interventions to reduce the risk of fatal 
outcomes [2]. Currently, the epidemiological situation is 
cause for concern especially with regard to AMR Gram-
negative pathogens, e.g. characterised by carbapenem 
resistance (CR) [3]. However, the Gram-positive meticil-
lin-resistant Staphylococcus aureus  (MRSA) is still one 
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of the most important causes of healthcare-associated 
infections due to AMR pathogens [3].
In 2017 in a consensus report of the European 
Centre for Disease Prevention and Control (ECDC), 
the European Food Safety Authority (EFSA) and the 
European Medicines Agency (EMA), the proportion of 
MRSA in invasive  S. aureusinfections was proposed 
as an indicator for surveillance of AMR pathogens in 
humans [4]. Although in 2016 the proportion of MRSA 
in invasive  S. aureus  infections in Europe reached its 
lowest level (13.7%) since the ECDC first presented 
population-weighted data for the EU in 2009, large 
inter-country variations (1.2 to 50.5%) remain in Europe 
[3]. For example, in the most populated German federal 
state, North Rhine-Westphalia (NRW), the incidence of 
MRSA bacteraemia per inhabitants was 32-fold higher 
compared with the Dutch neighbouring region with 
similar population size in 2009–10 [5].
The occurrence of MRSA still necessitates continu-
ous surveillance and preparedness to optimise IPC to 
further decrease MRSA rates [6-9]. Since 1999, MRSA 
screening of various sites including at least nares, phar-
ynx and wounds (if present) and additionally perineum 
or groin (in case of known previous carriage) before or 
at admission to hospitals is recommended in Germany, 
if patients have defined risk factors [10]. For MRSA car-
riers IPC measures including isolation in single rooms, 
barrier precautions and decolonisation therapies are 
also recommended [10,11]. Within the EU-funded com-
munity initiative INTERREG IIIA in 2006, all hospitals in 
the German Münsterland region, located directly at the 
Dutch–German border, started to establish a network 
to control MRSA – the EUREGIO MRSA net. They agreed 
to monitor the implementation of the IPC measures, 
harmonise local standards, exchange hospital utilisa-
tion data and MRSA data, perform molecular typing of 
Figure 
Location of the study region in the Netherlands and Germany, 2012–2016














Study region in Netherlands
Study region in Germany
The light orange area represents the study region within the Netherlands, including the Dutch regions East Groningen (NL111), Delfzijl and 
surroundings (NL112), rest of Groningen (NL113), North Drenthe (NL 131), South East Drenthe (NL132), South West Drenthe (NL133), Twente 
(NL213), Achterhoek (NL225). The light blue area represents the study region within Germany, including the Grafschaft Bentheim region 
(DE94B) and the Münsterland-region with the urban district Münster (DEA33) and the rural districts Borken (DEA34), Coesfeld (DEA35), 
Steinfurt (DEA37) and Warendorf (DEA38).
3www.eurosurveillance.org
Table 1
Risk factors for MRSA carriage at admission according to Dutch and German MRSA guidelines, 2012–2016
MRSA carriage risk factors
Defined risk factors for MRSA screening according to national guideline/recommendation
Germany Netherlands
(Previous) MRSA carriage or 
infection
Known MRSA carrier or previous MRSA 
carriage or infection
Known MRSA carrier (RMRSA)
(Previous) MRSA carrier who underwent decolonisation, 
without three consecutive negative MRSA screening tests, 
taken at least 7 days apart (RMRSA)
(Previous) MRSA carrier who underwent decolonisation, 
with three consecutive negative MRSA screening tests, 
taken at least 7 days apart, and is within 1 year follow-up 
after first negative MRSA test (RL)
Contact to MRSA positive person Contact with another person with MRSA carriage or infection (same room)
Unprotected contact within the last 2 months: 
 
- Inside hospital: part of ring investigation (RH) 
 
- Outside hospital: household member, partner or 
caregiver of MRSA positive person (RH)a 
 
- Contact to MRSA positive healthcare worker, regardless 
of duration (RL)
Persistent unprotected exposure: negative MRSA screening 
test within the last 3 months (RL)
Recent stay in other healthcare 
institution
Hospitalisation for > 3 days within the 
previous 12 months
Stayed in a foreign healthcare institution within the last 2 
months (RH), and: 
 
- stayed more than 24 hours, or 
 
- stayed less than 24 hours plus at least one secondary 
risk factor (invasive procedure, chronic infections, 
persistent skin lesions, abscesses or furuncles) for MRSA 
carriage
Stayed in a foreign healthcare institution more than 2 
months ago plus at least one secondary risk factor (see 
above) for MRSA carriage (RL)
Direct transfer of the patient from 
facilities in regions with known high MRSA 
prevalence (i.e. including all German 
healthcare facilities)
Previous hospitalisation within the last two months in 
a Dutch healthcare institution in a department with an 
ongoing MRSA outbreak (RH)
Haemodialysis patients All haemodialysis patientsb
- Patient usually dialysed abroad (i.e. ‘home dialysis 
center’ abroad), now dialysed in the Netherlands (i.e. 
guest dialysis patients) (RH) 
 
- Patient usually dialysed in the Netherlands (i.e. Dutch 
‘home dialysis center’) dialysed abroad within the last two 
months (RL)
Contact to livestock Regular professional direct contact to livestock (swine, cattle, poultry)c
-Contact to live pigs/meat calves/broilersc regardless of 
whether this contact was professional or not and/or lives 
on a farm where these animals are kept (RH) 
 
- Persistent exposure: negative MRSA screening test within 
the last 3 months (RL)
Other risk factors
Chronic skin lesions - Children adopted from abroad and living in the 
Netherlands (RH) 
 
- Stayed in a home for asylum seekers within the last two 
months (RH)d
Need for long-term care plus one of 
the following risk factorsb: (i) receipt of 
antibiotics during the previous 6 months, 
or (ii) presence of indwelling devices
MRSA: meticillin-resistant Staphylococcus aureus; RMRSA/RH/RL: risk categories corresponding to different levels of isolation for inpatients.
a Added in December 2012.
b Modified in 2012–13: patient with two or more of the following risk factors: need for long-term care, receipt of any antibiotics during the 
previous six months, presence of indwelling devices, need for haemodialysis, skin lesions and burns.
c Modified; in 2012–13 only swine.
d Added in October 2015.
The levels of isolation for inpatients with risk categories were the following: (RMRSA) MRSA positive- or (RH) high-risk category patients 
in high-risk departments of the hospital (e.g. intensive care unit, haematology): single room isolation with contact- and airborne 
precautions. (RH) High-risk category patients who are not in high risk departments and who have an MRSA screening result available within 
24 hours of admission: single room with contact precaution. (RL) Low-risk category: no isolation, awaiting new MRSA screening test results.
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MRSA isolates and establish regional benchmarks [12]. 
This ‘search-and-follow’ strategy was inspired from the 
‘search-and-destroy’ policy implemented in Dutch hos-
pitals since the 1980s. It aimed to improve application 
of the German national MRSA recommendations, the 
regional cooperation between hospitals, other health-
care facilities and public health authorities, as well 
as to create a more robust MRSA surveillance system 
[9,12-14]. Further to this strategy, screening for MRSA 
carriage among risk patients at hospital admission 
increased between 2009 and 2011 in these regional 
German hospitals and the nosocomial MRSA incidence 
density significantly decreased [15].
The cross-border IPC network cooperation, i.e. the 
Dutch−German web-based communication portal 
for handling MRSA problems for healthcare workers, 
patients and the public was continued from 2009 to 
2015 within the INTERREG IVA funded project EurSafety 
Health-net. This enabled hospitals and nursing homes 
to acquire Euregional Quality and Transparency cer-
tificates. Moreover, since 2016, the collaboration was 
further prolonged within the INTERREG VA funded pro-
ject EurHealth-1Health inter alia. Within this, the Dutch 
signaling meeting of the Hospital-acquired Infection 
and Antimicrobial Resistance Monitoring Group (SO-ZI/
AMR) occurs in the German study region.
Here, we analysed 2012 to 2016 MRSA surveillance 
data from Dutch and German border region hospi-
tals (NL-BRH and DE-BRH) in the network in order to 
describe temporal and spatial trends of MRSA rates 
and find differences between these groups of hospi-
tals. We also used the data to calculate the MRSA rates 
per inpatient and per patient days in both groups of 
hospitals and the MRSA rates per inhabitants in the 
patient catchment areas of NL-BRH and DE-BRH respec-




Within the EurSafety Health-net project (http://
www.eursafety.eu/) the German part of the project 
region geographically comprised six districts in the 
Münsterland region (codes DEA33–35, DEA37, DEA38 
and DE94B, level 3, according to the Nomenclature 
of Territorial Units for Statistics, NUTS [16]) and was 
inhabited by ca 1.73 million people [17]. The Dutch part 
comprised eight districts in the provinces of Groningen, 
Drenthe and in the region Twente-Achterhoek (codes 
NL111–113, NL131–133, NL213 and NL225) inhabited 
by ca 2.10 million people (Figure) [17]. Initially, there 
were 42 hospitals located in the Dutch–German region 
(reduced in 2015 to 41 due to a structural merging of 
two DE-BRH) treating ca 620,000 admitted patients 
(68.0% in the German part of the study region) with 
ca 3,900,000 patient days per year. All 34 (since 2015, 
33) regional DE-BRH (9.5% of hospitals in NRW in 2016) 
and all eight regional NL-BRH (8.8% of hospitals in the 
Netherlands in 2016) took part in the project. Among 
the DE-BRH, 29 were acute care hospitals, one was a 
university hospital, one was a rehabilitation clinic and 
three hospitals were specialised in psychiatry, while 
the NL-BRH comprised one university- and seven acute 
care hospitals.
Table 2
Numbers of meticillin-resistant Staphylococcus aureus cases documented in all study hospitals in the German region of 
Münsterland and the Dutch regions of Twente-Achterhoek, Drenthe and Groningen, 2012–2016 (n = 42 hospitals)a
Region, country (number of BRH) MRSA cases
Year
2012 2013 2014 2015 2016




MRSA (total) 4,453 100.0 4,481 100.0 4,391 100.0 4,418 100.0 4,122 100.0
Nosocomial MRSA casesb 430 9.7 361 8.1 316 7.2 266 6.0 260 6.3





MRSA (total) 216 100.0 295 100.0 308 100.0 321 100.0 327 100.0
MRSA cases with known 
status imported or 
nosocomialb
77 35.6 133 45.0 134 43.5 143 44.5 133 40.7
Nosocomial MRSA casesb 10 13.0b 16 12.0b 22 16.4b 18 12.6b 14 10.5b
MRSAB cases 5 NA 12 NA 11 NA 12 NA 3 NA
DE-BRH: German border region hospitals; MRSA: meticillin-resistant Staphylococcus aureus; MRSAB: MRSA isolated from blood cultures; NA: 
not applicable; NL-BRH: Dutch border region hospitals.
a From 2015 onwards, the number of DE-BRH was reduced to 33. This implies that the total number of hospitals in the study region became 41 
after 2015.
b Data about the classification of cases as ‘nosocomial’ or ‘imported’ were only available for German hospitals, Dutch hospitals in the 
Twente-Achterhoek region and since 2013, for one hospital in Groningen, Netherlands. The given percentages refer to the percentages of 
nosocomial cases among those MRSA cases for whom this information was documented.
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Guidelines for patients at risk for meticillin-
resistant Staphylococcus aureus and infection 
prevention and control measures
Both NL-BRH and DE-BRH implemented MRSA-related 
IPC measures according to their national guidelines 
and recommendations, issued by the Dutch Working 
Group on Infection Prevention (WIP) and the German 
Commission for Hospital Hygiene and Infection 
Prevention (KRINKO) at the Robert Koch-Institute, 
respectively [10,18]. Of note, the definitions of whom 
to screen at admission differed for NL-BRH and DE-BRH 
based on the national guidelines and recommenda-
tions (Table 1), as well as screening sites (DE-BRH: at 
least nose, pharynx, throat and wounds, if present, 
additionally perineum and groin swab, when indicated; 
NL-BRH: nasal-, throat- and perineum or rectum swab 
plus additional cultures depending on clinical signs) 
[10,19]. In all hospitals positive screenings or any other 
detection of MRSA was followed by single room isola-
tion, contact precautions and decolonisation, if appli-
cable. Pre-emptive isolation of patients with MRSA risk 
factors was performed according to local guidelines (in 
DE-BRH only for patients with previous MRSA carriage, 
for NL-BRH see Table 1. In both countries adherence to 
the MRSA-IPC guidelines- and recommendations was 
periodically checked by the responsible local pub-
lic health authorities (Germany) and national health 
inspectorate (Netherlands). The implementation of 
other IPC measures in the participating hospitals, such 
as standards for the prevention of catheter-related 
bloodstream infections, was not planned or assessed 
within the project.
Data collection
An MRSA case was defined as an inpatient who was 
colonised or infected with MRSA at admission or for 
nosocomial MRSA cases, after admission. A blood cul-
ture positive for MRSA, from a single inpatient and from 
a single hospital stay was qualified as MRSAB case. If 
an MRSA case, or MRSAB case, had several stays in a 
year, each hospital stay was counted as an MRSA case, 
or MRSAB case, in the surveillance.
On both sides of the border, the collected surveillance 
data of inpatients (i.e. excluding outpatients) included 
the number of nasopharyngeal swabs performed for 
MRSA screening before or at admission, the numbers 
of MRSA cases (one isolate per patient per hospital 
Table 3
Annual medians of meticillin-resistant Staphylococcus aureus parameters in all study hospitals in the German region 
Münsterland and the Dutch regions of Twente-Achterhoek, Drenthe and Groningen, 2012–2016 (n = 42 hospitals)a
Region, country (number of BRH) MRSA parameter
Year(s)







































































































































BRH: border region hospitals; DE-BRH: German BRH; IQR: interquartile range; MRSA: meticillin-resistant Staphylococcus aureus; MRSAB: MRSA 
isolated from blood cultures; NL-BRH: Dutch BRH; SAB: S. aureus isolated from blood cultures.
a Since 2015 the number of DE-BRH was reduced to 33. This implies that the total number of hospitals in the study region became 41 after 
2015.
b Only available for German hospitals, Dutch Twente/Achterhoek hospitals and, since 2013, for one Groningen hospital, Netherlands.
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stay) − in DE-BRH and in several NL-BRH MRSA cases 
were additionally classified as imported or nosoco-
mial (i.e. nosocomial, if the case was detected ≥ 3 
days after hospital admission unless the patient was 
a known MRSA carrier), the number of cases and the 
number of patient days. Additionally, in DE-BRH and 
in several NL-BRH the patient days of MRSA cases (i.e. 
the number of days, which an MRSA-positive patient 
spent in hospital) were also recorded. Moreover, the 
number of inpatients with a blood culture positive for 
MRSA (MRSAB, one isolate per patient case) and the 
number of S. aureus  in blood cultures (one isolate per 
patient case) were assessed. The MRSA-surveillance 
data as described above were collected in all DE-BRH 
using a protocol adapted from the national German 
Nosocomial Infections Surveillance System (MRSA-
KISS [20]); see Supplement Table S1). For cross-border 
analysis, the laboratories serving for all NL-BRH pro-
vided retrospectively collected data for the period 2012 
to 2016, according to the same protocol.
Ethical statement
Ethical approval was asked from ethical committee at 
the University Medical Center Groningen (UMCG) and 
approval was not necessary for this study.
Data analysis
We analysed the surveillance data of 5 years (2012–16) 
and calculated the following parameters: (i) screening 
rate (nasopharyngeal swabs for MRSA/100 inpatients), 
(ii) MRSA incidence (MRSA cases/100 inpatients), (iii) 
percentage of MRSA isolates per all S. aureus  isolates 
detected in blood cultures, (iv) incidence density of 
MRSA isolates detected from blood cultures (MRSAB 
cases/100,000 patient days), (v) nosocomial MRSA 
incidence density (nosocomial MRSA-cases/1,000 
patient days), (vi) length of stay in hospital (number 
of patient days/inpatients, (vii) length of stay in the 
hospital of MRSA cases (number of patient days of 
MRSA cases/MRSA cases). We calculated the mean 
annual numbers of inpatients per 100 inhabitants 
and of patient days per 100 inhabitants of the patient 
catchment area of NL-BRH and DE-BRH. Furthermore, 
we calculated the mean annual number of nasopharyn-
geal swabs performed for MRSA screening before or at 
admission to hospital per 100 inhabitants in the patient 
catchment area of the regional hospitals (DE-BR and 
NL-BR) as well as of inpatient MRSA cases per 1,000 
inhabitants and the MRSAB/1,000,000 inhabitants 
using our surveillance data of inpatients (i.e. excluding 
outpatients). The number of inhabitants were assessed 
from the official statistical database [17].
Time trends of MRSA parameters were analysed by 
Friedman tests. The percentage of nosocomial MRSA 
cases on all MRSA cases was assessed by Cochran–
Armitage test of linear trend. The cross-border regional 
comparisons were analysed using Wilcoxon rank sum 
test. All statistical analyses were done using SAS 9.4 
software (SAS Institute Inc., Cary, United States); 
p < 0.05 was considered significant. Results of signifi-
cance tests were discarded if the software displayed 
an alert due to more than 10% of missing values in 
the respective dataset. The map was made using 
RegioGraph10 (GFK Geomarketing GmbH, Bruchsal, 
Germany).
Table 4
Meticillin-resistant Staphylococcus aureus parameters in all study hospitals in the German region of Münsterland and the 









p value (median 
comparison)
Meanb Median (IQR) Meanb Median (IQR)
Nasopharyngeal swabs for MRSA 
screening/100 inpatients (%) 50.2 42.3 (33.8–56.8) 3.9 3.0 (0.6–5.1) < 0.0001
MRSA cases of colonisation and/or 
infection/100 inpatients 1.04 1.04 (0.77–1.36) 0.15 0.14 (0.10–0.20) < 0.0001
MRSAB/SAB (%) 9.8 10.2 (3.0–21.5) 1.5 0.3 (0.0–4.0) < 0.0001
MRSAB/100,000 patient days 2.30 1.55 (0.00–3.53) 0.83 0.26 (0.00–1.72) 0.0041
Nosocomial MRSA cases/1,000 patient 
daysc 0.11 0.09 (0.03–0.14) 0.03 0.03 (0.02–0.04) 0.0002
LOS in the hospital 6.9 6.8 (5.7–9.4) 5.3 4.9 (4.7–5.4) < 0.0001
LOS of MRSA patientsd 11.4 11.1 (8.5–14.2) 12.1 11.7 (5.6–17.5) 0.8774
DE-BRH: German border region hospitals; IQR: interquartile range; LOS: length of stay; MRSA: meticillin-resistant Staphylococcus aureus; 
MRSAB: MRSA isolated from blood cultures; NL-BRH: Dutch border region hospitals; SAB: S. aureus isolated from blood cultures.
a Since 2015 the number of DE-BRH was reduced to 33. This implies that the total number of hospitals in the study region became 41 after 
2015.
b Pooled mean value.
c Only available for German hospitals, Dutch Twente-Achterhoek hospitals and, since 2013, for one Groningen hospital, Netherlands.
d Only available for German hospitals, two Dutch Twente-Achterhoek and two Groningen hospitals.
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Results
Trend and cross-border comparison of 
meticillin-resistant Staphylococcus aureus rates
The total numbers of MRSA cases (detected in DE-BRH 
and NL-BRH are shown in Table 2. In both DE-BRH and 
NL-BRH the median nasopharyngeal MRSA screening 
rate increased significantly between 2012 and 2016 
(Table 3). Overall, the median screening rate was 14 
times higher in DE-BRH than in NL-BRH (p < 0.0001, Table 
4).
The median MRSA incidence remained stable over time 
at both sides of the border (Table 3), but was more than 
seven times higher in DE-BRH than in NL-BRH (p < 0.0001) 
(Table 4). The median percentage of MRSA on  S. 
aureus blood culture isolates decreased from 12.5% in 
2012 to 5.0% in 2016 in DE-BRH (p = 0.0959), while it 
remained stable in NL-BRH (p = 0.1679) (Table 3), but 
was more than 34 times higher in DE-BRH (p = 0.0001) 
(Table 4). The median of MRSAB per 100,000 patient 
days remained stable over time in DE-BRH (p = 0.4272) 
and NL-BRH (p = 0.0620) (Table 3) and was six fold 
greater in DE-BRH than in NL BRH (p = 0.0041) (Table 
4). The percentages of nosocomial cases on all MRSA 
cases (Table 2) decreased significantly in DE-BRH 
(p < 0.0001), but did not change in NL-BRH (p < 0.6474). 
Over the study period the median nosocomial MRSA 
incidence-density decreased significantly in DE-BRH 
(p = 0.0184) (Table 3), but did not change in NL-BRH 
(p = 0.3532) and was approximately three times higher 
in DE-BRH than in NL-BRH (p = 0.0002) (Table 4).
Cross-border comparison of healthcare 
utilisation
We compared the available data on healthcare utilisa-
tion in DE-BRH and NL-BRH. The median length of stay 
(LOS) in the hospital was 6.8 days in DE-BRH compared 
with 4.9 days in NL-BRH (p < 0.0001) (Table 4); LOS of 
MRSA patients was similar in DE-BRH vs NL-BRH (11.1 
days vs 11.7 days; p = 0.8774) (Table 4). The hospi-
talisation rate was 24.3 inpatients/100 inhabitants 
annually in the patient catchment area of DE-BRH, 
almost thrice the rate in the NL-BRH’s catchment area 
(9.27/100). To put this difference in healthcare utilisa-
tion into context, we calculated the mean annual num-
ber of nasopharyngeal MRSA screening swabs before 
or at admission to hospital per 100 inhabitants in the 
German border region (DE-BR) vs the Dutch border 
region (NL-BR) (12.2 vs 0.36). Additionally, we com-
pared the MRSA surveillance data of inpatients (i.e. 
excluding outpatients) in the patient catchment area 
of DE-BRH and NL-BRH. The calculated the number of 
inpatient MRSA cases per 1,000 inhabitants in DE-BR 
and NL-BR were 2.52 vs 0.14. Furthermore, the cal-
culated MRSAB/1,000,000 inhabitants in DE-BR and 
NL-BR was 38.4 vs 4.09 (Table 5).
Discussion
As patients in the EU have the right to healthcare 
across the borders of Member States (EU directive 
2011/24/EU), it is of interest to compare the quality of 
care, safety standards and risks of nosocomial infec-
tion by AMR pathogens between EU countries. In this 
respect, the cross-border systematic and continuous 
MRSA surveillance is one of the cornerstones to ensure 
equal quality of healthcare [21].
Our study revealed significant differences between 
Dutch and German hospitals (Table 4). The median 
MRSA-incidence in DE-BRH was more than seven times 
higher compared with NL-BRH. We also found that 
the median MRSA percentage of  S. aureus  detected 
in blood cultures was more than 34 times higher in 
DE-BRH than in NL-BRH (Table 4). The incidence den-
sity of MRSAB was six times higher in DE-BRH (Table 4) 
and there were nine times more MRSAB per 1,000,000 
Table 5
Calculated parameters in the patient catchment area of all study hospitals in the German region of Münsterland and Dutch 
regions of Twente-Achterhoek, Drenthe and Groningen, 2012–2016 (n = 42 hospitals)a
Parameter




Groningen, Netherlands (NL-BR)b 
 
Meanc
Inpatients/100 inhabitants 24.3 9.27
Patient days/100 inhabitants 167.2 49.0
Nasopharyngeal swabs for MRSA screening before or at admission 
to hospital/100 inhabitants 12.2 0.36
Inpatient MRSA cases of colonisation and/or infection/1,000 
inhabitants 2.52 0.14
MRSAB/1,000,000 inhabitants 38.4 4.09
DE-BR: German border region; MRSA: meticillin-resistant Staphylococcus aureus; MRSAB: MRSA isolated from blood cultures.
a Patient catchment area of 34 (since 2015: 33) German border region hospitals. This implies that the total number of hospitals in the study 
region became 41 after 2015.
b Patient catchment area of eight Dutch border region hospitals.
c Pooled mean value.
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inhabitants for the patient catchment area of DE-BRH 
compared with NL-BRH (Table 5).
According to the ECDC, differences in the occurrence of 
AMR pathogens between European countries are most 
likely caused by differences in healthcare utilisation, 
antimicrobial use and IPC practices [3].
Concerning healthcare utilisation in our context, we 
found that inhabitants in the German part of the study 
region were almost three times as often hospital-
ised (Table 5) and had a significantly longer LOS than 
patients on the Dutch part (Table 4). This may be due 
to socioeconomic factors or a different organisation of 
ambulatory healthcare.
While antimicrobial consumption was not the focus of 
the current study, NRW has been reported as the region 
in Germany with the highest antimicrobial consumption 
in outpatients (19.2 daily defined doses (DDD/1,000 
inhabitants) [22]. In this respect, the MRSA incidence 
in DE-BRH was slightly above the incidences in German 
hospitals participating in the nationwide surveillance 
system MRSA-KISS [20]. The antimicrobial consump-
tion level in NRW seems to be also considerably higher 
than in the Netherlands (10.39 DDD/1,000 inhabitants) 
[23], not only in terms of total antibiotics consumed, 
but also for the oral use of second-generation cepha-
losporins. Promoting rational regional antibiotic use 
is therefore one of the major goals in the INTERREG 
VA project EurHealth-1Health (http://www.eurhealth-
1health.eu/).
For MRSA IPC, the recommendations in Germany and 
the corresponding guidelines in the Netherlands were 
comparable regarding the measures performed for 
MRSA carriers [10,18]. However, there were differences 
between the two countries in identifying people at risk 
of MRSA infection/colonisation [10,18]. In this study, 
we found that the DE-BRH performed 14 times more 
nasopharyngeal screening swabs for MRSA than their 
Dutch counterparts.
The higher screening rates on the German side of the 
border may be ascribed to the fact that in German IPC 
recommendations, previous hospitalisation in Germany 
is a risk factor for MRSA carriage. This constitutes a main 
difference in defined risk factors between Dutch- and 
German MRSA IPC guidelines, whereby Dutch guide-
lines mostly consider screening for patients previously 
hospitalised outside the Netherlands (Tables 1  and  3) 
[14,24]. In this respect, we observed that although 
the densities of nosocomial MRSA cases were lower 
in NL-BRH than in DE-BRH (Table 3), the proportion of 
nosocomial MRSA cases among all MRSA detected was 
slightly higher in the Dutch hospitals (Table 2). The 
reason for this remains unclear, but it might be specu-
lated that a larger proportion of MRSA carriers in the 
Netherlands had no risk factors for MRSA and were 
hence not screened at admission.
Another explanation for screening rate differences 
between the two countries may be distinct underlying 
epidemiological situations regarding MRSA. For exam-
ple, the MRSA prevalence is higher in the population in 
Germany than that in patients at hospital admission in 
the Netherlands (0.7% vs. 0.13%) [25,26]. Moreover in 
the German part of the study region, a possible addi-
tional MRSA burden due to the exceptionally frequent 
occurrence of livestock-associated MRSA might have 
an effect [27,28].
The screening and IPC measures in the DE-BRH 
appeared to be nevertheless appropriate. In 2006, in 
the project region excluding Groningen and Drenthe 
(Figure), investigations evaluating the numbers of 
patients with MRSA risk factors at admission to German 
hospitals demonstrated that ca 35.6% of patients had 
a risk factor requiring screening [29]. A corresponding 
level of screening was implemented by DE-BRH during 
the study period 2009–11 [15]. This level remained high 
in the 2012–16 period (Table 3), indicating a very good 
implementation of the screening standards.
About 1% of all patients admitted in DE-BRH carried 
MRSA, which corresponds well to results of investiga-
tions evaluating the prevalence of MRSA carriage in 
the regional general, non-hospitalised population in 
2012 [25]. In terms of difference with the Netherlands, 
this has for consequence that it is more expensive to 
provide isolation capacities for ca 1.0% of inpatients 
with MRSA in DE-BRH vs 0.15% in NL-BRH. Moreover, 
the higher MRSA incidence in DE-BRH could lead to a 
higher probability for nosocomial MRSA cases as they 
are not completely avoidable [30-32].
From 2012 to 2016 however, the nosocomial MRSA 
incidence density in DE-BRH decreased significantly, 
a trend already observed from 2009 to 2011 [15]. 
Moreover, the nosocomial MRSA incidence density 
(Table 3) appeared to be below the densities reported 
for hospitals participating in the nationwide surveil-
lance system MRSA-KISS (median nosocomial MRSA 
cases per 1,000 patient days in DE-BRH/MRSA KISS, 
2012–16: 0.11/0.14, 0.09/0.12, 0.09/0.10, 0.08/0.09, 
0.07/0.08) [15,20]. This may indicate the successful 
implementation of concerted IPC standards in DE-BRH 
in the EurSafety Health-net network [15].
We also observed for that the difference of the inci-
dence of MRSA bacteraemia per inhabitants between 
the German and Dutch border region (38.4 vs 4.09 
per 1,000,000) was apparently smaller than calcu-
lated in a previous study, which used 2009 Dutch and 
2010 German data respectively to derive the differ-
ence between NRW and the Netherlands (57.6 vs 1.8 
per 1,000,000) [5]. In addition, according to the pop-
ulation-based German mandatory notification system 
for invasive MRSA infections (SurvStat) from 2012 to 
2016, 40.7 MRSA isolates were detected in blood or 
cerebrospinal fluid per 1,000,000 inhabitants in the 
German project region [33], which is lower compared 
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with data from the federal state of NRW (70.3 per 
1,000,000 inhabitants) as well as from Germany (47.9 
per 1,000,000 inhabitants) [34].
Comparing our results with those of other German lab-
oratories participating in a voluntary, national surveil-
lance system (ARS) [35], revealed that, for each year of 
the period 2012–16 the median percentage of MRSA 
in  S. aureusfrom blood cultures was lower in DE-BRH 
than in other laboratories in western Germany (DE-BRH/
ARS-region west (NRW), 2012–16: 12.5%/19.0%, 
14.3%/15.0%, 10.5%/13.5%, 9.8%/13.3%, 5.0%/12.0%) 
(Table 3), as well as below the middle lower range of 
the EU/European Economic Association (EEA) popula-
tion-weighted mean between 18.8% in 2012 and 13.7% 
in 2016 [3,34,36].
In contrast, the mean MRSA percentage of  S. 
aureus  detected in blood culture during 2012–16 
was higher (1.5% vs 1.3%) in NL-BRH compared with 
Dutch national data of Infectious Disease Surveillance 
Information System for Antibiotic Resistance, (ISIS-AR) 
covering data of 52% of diagnostic laboratories [37].
As typical for all passive surveillance systems, bias 
due to differences in reporting behaviour cannot be 
excluded and is a limitation of this study. However, as 
MRSA surveillance in DE-BRH started in 2007, a sta-
bilised compliance in reporting can be assumed for 
the period from 2012–16. The higher number of MRSA 
cases per inhabitants on the German side compared 
with the Netherlands is biased if there is more than 
one episode of MRSA detection per year for one indi-
vidual patient among the number of cases. Also the 
inclusion of three psychiatric hospitals and one reha-
bilitation clinic, which have usually longer average 
lengths of stay, may have prolonged hospital stay in 
the DE-BRH. However, the data are in accordance with 
German-wide assessment systems. The clinical rel-
evance of MRSA isolates detected in blood cultures is 
undisputable, but variations in blood culture diagnos-
tics (e.g. frequency, performance) may result in bias 
when comparing MRSA percentages of S. aureus blood 
culture isolates between different countries [38]. A 
limitation of the study design is that the implementa-
tion of IPC standards, which are not directly targeted to 
control MRSA, such as bundles to prevent central-line-
associated bloodstream infections (CLABSI), was not 
assessed and compared in the participating hospitals. 
Hence, changes of the incidence of MRSA bacteraemia 
could also be attributable to improvements in CLABSI 
prevention or other IPC standards.
This study on MRSA covering all hospitals across part 
of a European border as well as hospitals of all three 
care-categories demonstrated that routine MRSA sur-
veillance may be helpful to monitor trends of MRSA 
parameters, to compare the MRSA rates and to indi-
cate needs for further improvement to reach low MRSA 
rates EU-wide. Our results supplement the European 
and national surveillance systems. Ongoing efforts 
in MRSA prevention are recommended, including all 
healthcare sectors, especially with focus on One Health 
[39-42]. Moreover, cross-border surveillance should be 
extended to other multidrug-resistant organisms, such 
as CR Enterobacteriaceae in the future.
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